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ABSTRACT
Background: Randomised controlled trials (RCTs)
are considered particularly likely to benefit from patient
and public involvement (PPI). Decisions made by
professional researchers at the outset may go on
to have a significant impact on the potential for PPI
contributions.
Objective: To increase knowledge of PPI within the
early development of RCTs by systematically describing
the reported level, nature and acceptability of proposed
PPI to the funders.
Methods: Documentation from the outline
application process for all RCTs that received funding
from the Health Technology Assessment (HTA)
Programme 2006–2010 was requested. For each
application, data were extracted on trial characteristics,
references to PPI in the development of the outline
application and funding Board feedback, and plans for
PPI in the full application and after the trial was
funded.
Results: 110 applications were eligible with outline
applications available for 90 (82%). The cohort covered
a wide range of interventions and conditions. 54% (49/
90) provided some information about PPI. 26 (28.9%)
indicated PPI within the development of the outline
application itself; 32 (35.6%) planned involvement in
the full application and 43 (48%) once the trial was
funded. Recruitment at diagnosis and surgical
interventions were less likely to describe PPI. Blinded
trials and trials in which participants may receive
placebo only, more frequently described PPI activity.
The HTA commissioning Board feedback rarely referred
to PPI.
Conclusions: Incorporation of PPI within the
development of the outline application or specification
of plans for future involvement was low. Funder
requests for applicants to provide information on PPI
and justification for its absence should be welcomed
but further research is needed to identify the impact of
this on its contributions to research. Comments on PPI
by reviewers should be directional rather than state
that an increase is required. Challenges facing
applicants in initiating PPI prior to funding need to be
addressed.
BACKGROUND
Public involvement in research is described
as research being carried out ‘with’ or ‘by’
members of the public rather than ‘to’,
‘about’ or ‘for’ them (http://www.invo.org.
uk/ﬁnd-out-more/what-is-public-involvement-
in-research-2/, last accessed 5 September
2013). It has been suggested that clinical
trials are particularly likely to beneﬁt from
patient and public involvement (PPI).1 2 PPI
can start at various stages of a trial and inﬂu-
ence many aspects. Increased recognition
that patients and public are stakeholders in
research has led to increasing calls that they
Strengths and limitations of this study
▪ This is the first study to systematically investigate
patient and public involvement (PPI) early in the
development of funding applications and across
a wide range of trials.
▪ Presents results of a large unselected cohort
addressing concerns of selective reporting of
case studies within the literature.
▪ Is the first study to consider clinical and trial
characteristics in relation to the model of PPI
adopted.
▪ Cohort is limited to a single funder covering all
randomised controlled trials receiving funding
between 2006 and 2010.
▪ Documentation could not be made available for
unsuccessful applications. However, PPI was not
mandatory within the period of the cohort, and
that on its own would not have led to a decision
that the outline application should not progress.
▪ As the cohort was identified by receipt of
funding during the period rather than the year
that the outline application was submitted for
consideration, fewer trials were available in the
extremes of the cohort.
▪ Changes to funder requirements for PPI have
changed and this may impact generalisability.
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be represented within that research process. The UK
Department of Health (2006) Best Research for Best Health
guidelines3 state that PPI must be included in all stages of
the research process including priority setting, deﬁning
research outcomes, selecting research methodology,
patient recruitment, interpretation of ﬁndings and dis-
semination of results. Many funding bodies now request
researchers to provide evidence of PPI when submitting
their proposals.4 The National Institute of Health
Research (NIHR) Health Technology Assessment (HTA)
programme encourages applicants to consider whether
the ‘scientiﬁc quality, feasibility or practicality of the pro-
posal can be improved by patient and public involve-
ment’ (http://www.hta.ac.uk/public/).
Staniszewska et al5 discussed the importance of PPI
being implemented at the design stage of studies to opti-
mise the impact and relevance of research. During the
design stages of a trial many decisions are made that
determine the relevance and conduct of the proposed
research: the precise speciﬁcation of the research ques-
tion, including the outcomes to be measured; visit sche-
dules; methods of data collection; recruitment and
consent procedures. Fudge et al6 suggest that decisions
made by professional researchers at the outset of a study
have a cumulative and signiﬁcant inﬂuence on the
potential for PPI to impact on a study and that involve-
ment is more difﬁcult to achieve once studies are under
way. It is therefore important to consider PPI activity in
the early stages of the research process. However, little is
known about how or when researchers incorporate PPI
or what impact may stem from that involvement.
Concerns have been expressed that the existing litera-
ture is selectively reported with many reports aiming to
‘make the case’ or ‘convince the sceptics’ about PPI.7
Furthermore, as much reporting has involved single case
studies, generalisability of the PPI literature is limited.7
The aim of this paper is to increase the knowledge of
PPI within the early stage design and development of
clinical trials by systematically studying an unselected
cohort of outline applications that were in receipt of
funding from the HTA programme between 2006 and
2010. Speciﬁc objectives are to identify whether and how
PPI is described within the early development of a grant
application for funding; examine how PPI contributions
within the development of the outline application were
reviewed by the HTA Board; describe applicants’ PPI
plans should their application be successful; and
describe variations in PPI in relation to time of funding
and trial characteristics.
METHODS
We examined a cohort of randomised controlled trials
(RCTs) that received funding from the NIHR HTA) pro-
gramme in the UK between 2006 and 2010. During the
period of the cohort the HTA programme encouraged
PPI, and allowed for resources to support PPI activity to
be requested; however, PPI was not mandatory. Inclusion
of a PPI contributor on the Trial Steering Committee
(TSC) was recommended. The HTA programme has a
two-stage application process, comprising an outline
application followed by a full application for those suc-
cessful at the outline stage (http://www.hta.ac.uk/
funding/clinicaltrials/index.shtml, accessed 30 April
2012). We requested all documentation relevant to the
outline applications from the HTA. This comprised the
commissioning briefs (if applicable) in which the topic
of research driven by funders rather than applicants,
outline applications and the minutes of the relevant
Board meetings at which the outline applications were
considered and which contained feedback for the appli-
cant. Prior to the release of these documents the NIHR
HTA contacted the chief investigators of the trials
involved informing them that their names were released
as these were readily available within the public domain.
We signed a conﬁdentiality agreement and the NIHR
HTA redacted sensitive information regarding budget
information and names of co-applicants (not available
within the public domain) before releasing the docu-
mentation to us.
Once the trial was funded we established a PPI advis-
ory group of ﬁve members with experience of providing
PPI in RCTs. Members were recruited through an open
and transparent process. Advertisements for members
were placed on various PPI websites and applicants who
expressed an interest were sent an application pack
which included a detailed remit and role description.
Applicants were then short listed and invited to take
part in an informal interview over the phone, and had
the opportunity to ask further questions about the role
of the group. To assist in extracting and analysing the
information on PPI within the outline applications an
access database was developed by CG. The advisory
group commented on the data extraction tool and made
recommendations for changes to variable descriptors
and coding categories. All suggestions were discussed in
a face-to-face meeting and agreement reached on their
incorporation within the project.
Data were extracted to characterise the cohort and to
describe PPI activity within the application process and
plans for involvement once trial funding was secured.
Trial characteristics linked to trial complexity or thought
to be barriers or facilitators to recruitment8 were also
extracted. In brief, the extracted data included
characteristics of the trial design and setting, proposed
start date, disease or condition under study, type of inter-
vention, participant characteristics, recruitment setting
and any text that described or was relevant to PPI. Data
were extracted by three reviewers (LD, JP and CG). The
extracted text was anonymised by replacing any identify-
ing details with a general term in brackets [term], or
using [...] to indicate removed text (see online supple-
mentary table S1).
Text extracts were examined to determine whether
PPI had been described and if so whether PPI had been
undertaken during the development of the outline
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application (OL), was planned to occur during the
development of the full application (F) and/or was
planned to occur after a trial was funded (T). The text
was also examined to determine the role of the PPI con-
tributor’s input. This was categorised as: managerial
(M); responsive (R) and membership of Trial Steering
Committee (TSC). We categorised PPI contributors as
managerial if they were described as co-applicants or
involved in the management of the trial. We categorised
PPI contributors as having a responsive role if descrip-
tions of their input were largely conﬁned or targeted
towards a particular aspects of the application or trial, or
if PPI contributions were on an ‘as required’ basis.
Descriptions of PPI in the outline applications were
often limited, and we were therefore required to devise
coding ‘rules’ (based on our knowledge of grant applica-
tion development and clinical trial implementation pro-
cesses) in order to categorise the descriptions. The
codes were developed by CG and LD after reading the
PPI descriptions and then reviewed by JP. CG and LD
independently categorised the PPI descriptions.
Disagreements between CG and LD were discussed and
agreement reached. All categorisations were cross
checked by JP. The coding rules (box 1) and the classiﬁ-
cations (see online supplementary table S1) were
reviewed by the PPI advisory group and no changes were
requested.
The cohort was identiﬁed as RCTs that actively
received funding from the NIHR HTA programme
between 2006 and 2010. In considering trends over
time, the year the outline application was submitted was
used.
Speciﬁc conditions were selected to consider in more
detail. These were identiﬁed either by their strong
history of PPI or the establishment of an NIHR Clinical
Research Networks for a speciﬁc condition (http://www.
nihr.ac.uk/infrastructure/Pages/infrastructure_clinical_
research_networks.aspx, last accessed 5 September
2013). The categories were mental health, pregnancy
and childbirth, HIV/AIDS, cancer, stroke, paediatrics,
diabetes and dementias and neurodegenerative diseases.
Categorical data were summarised using descriptive
statistics with numbers and percentages. χ2 Tests or
Fishers exact tests were used as appropriate.
Ethical approval was obtained from the University of
Liverpool Institutional Ethics Board and the study was
funded by INVOLVE and managed by NIHR HS&DR.
RESULTS
Between 2006 and 2010, 111 RCTs received funding
from the NIHR HTA Programme. Of these 110 were
required to submit an outline application and were eli-
gible for inclusion within the cohort. The dates of sub-
mission of the associated outline applications were
between 2003 and 2008. Copies of the outline applica-
tions were available for 90 (82%) and comments from
the Board on the outline application were available for
77 (70%). There were ﬁve trials in which there was a dis-
agreement between data extractors, each of which
related to the presence/absence of PPI text and each
were resolved by referral to the application form.
Table 1 provides a summary of the conditions and
interventions. Trials were funded across a wide range of
clinical conditions, most of which were for long-term
conditions, with the most common area of study being
trials in mental health (17%). The majority of trials
(82.2%) were aimed at treatment of a condition with
14.4% being prevention trials. The trials used a wide
range of interventions. Over a third investigated a medi-
cinal product and just under a ﬁfth each evaluated
behavioural interventions (18.9%), surgical techniques
(17.8%) and devices (16.7%).
Table 2 describes the characteristics of trial partici-
pants and features of the trial designs. Over three-
quarters of the trials recruited adults only, with paediat-
ric trials accounting for 16.7% of the cohort. The
majority of the trials were not gender-speciﬁc and
approximately a quarter recruited participants at the
time of diagnosis. Trial recruitment was most commonly
conducted within secondary care (61%). Just under a
quarter of the trials involved blinding of the treating
clinical team or the participants. Just over 15% of trials
used a placebo with all participants receiving an active
intervention in one-third of these, indicating the use of
a double-dummy design. For example, in a double-
dummy trial comparing two treatments A and B trial
participants would receive either treatment A and a
placebo of treatment B, or a placebo of treatments A
and B.
Box 1 Coding rules used to inform the categorisation of
patient and public involvement (PPI) descriptions in outline
applications
Coding rules for categorising stage of involvement
1. If a PPI contributor is described as a member of the research
team or ‘lay member’ categorise them as inputting across all
future stages of the study.
2. The design of the study is determined within the full applica-
tion stage so if a PPI contributor is described as inputting
into the design of the study categorise their input as starting
no later than at development of the full application.
3. If a PPI contributor’s role is confined to Trial Steering
Committee membership (which is usually agreed by the
funders and follows the funding decision) categorise their
input as starting after the full application regardless of the
tense of the sentences describing their involvement.
Coding rules for categorising role
4 If a PPI contributor’s role is described as managerial or as a
co-applicant or referred to as a part of the team categorise
their role as managerial.
5 If a PPI contributor’s role is confined to a panel or an advisory
group categorise their contribution as responsive.
6 If a PPI contributor’s role is limited to a specific aspect of the
trial then categorise their input responsive.
Gamble C, et al. BMJ Open 2014;4:e005234. doi:10.1136/bmjopen-2014-005234 3
Open Access
group.bmj.com on December 19, 2014 - Published by http://bmjopen.bmj.com/Downloaded from 
Of the 90 outline applications for which documenta-
tion was available 49 (49/90=54%) provided some infor-
mation on PPI. Extracts from each application along
with the classiﬁcations on the stage and role of PPI are
provided in online supplementary table S1. Table 3 sum-
marises the classiﬁcations across the trials. The ﬁrst row
of table 3 shows that there were 19 applications in which
the text provided within the outline described PPI
occurring at all three stages (within the outline applica-
tion, full application and once the trial was funded). Of
these 19 applications the role was managerial (M) at
each stage in 13. In the remaining six there was variation
in the roles across the stages, or it was unclear when a
statement indicated that PPI would occur but no detail
was provided to allow classiﬁcation. An example of a
description that we were unable to categorise is:
Investigators have, and will continue to, collaborate with
service users.
Twenty-six applications (26/90=28.9%) speciﬁed a role
of PPI within the development of the outline applica-
tion. In 13 this was managerial, on a responsive basis in
seven, unclear in two and ‘other’ approaches used in
four (eg, a patient survey or pilot feedback). Within the
‘other’ approaches it was difﬁcult to determine conclu-
sively whether this was PPI or whether they were exam-
ples of data collection aimed at ascertaining the public
opinion. In the three applications that speciﬁed use of a
survey the extent of the distribution of the survey was
unclear in two. PPI was planned to occur within the full
application for 32 trials (35.6%). In 18 this was manager-
ial, responsive in 9 and unclear in 5. Forty-three (48%)
applications indicated that PPI was planned after the
trial was funded. This was as: managerial in 22;
Table 1 Summary of conditions and interventions
N=90
Number of
trials
n (%)
Long-term condition 51 (56.7)
Rare condition 2 (2.2)
Conditions expected to reduce lifespan 27 (30.0)
General shortening 14/27 (51.9)
Rapid mortality 13/27 (48.2)
Conditions under study*
Mental health 15 (16.7)
Heart disease/condition 3 (3.3)
Haematology/phlebology 7 (7.8)
Infections 7 (7.8)
Musculoskeletal 6 (6.7)
Cancer 3 (3.3)
Renal 4 (4.4)
Childbirth and pregnancy 2 (2.2)
Obstetrics and gynaecology 2 (2.2)
Addiction 4 (4.4)
Dermatology 2 (2.2)
Gastroenterology 6 (6.7)
Diabetes 2 (2.2)
Obesity/nutrition 3 (3.3)
Falls in the elderly 3 (3.3)
Sleep disorders 2 (2.2)
Stroke 4 (4.4)
Dental 2 (2.2)
Degenerative neurological disorders 4 (4.4)
Respiratory 4 (4.4)
Other 5 (5.6)
Aim of intervention
Treatment 74 (82.2)
Prevention 13 (14.4)
Diagnostic 3 (3.3)
Nature of interventions used*
Drug 31 (34.4)
Behavioural 17 (18.9)
Device 15 (16.7)
Surgery 16 (17.8)
Comparison with conservative
management (n=16)
7 (43.8)
Physical, eg, exercise 11 (12.2)
Educational 10 (11.1)
Community care 5 (5.6)
Other 4 (4.4)
Commissioned brief† 45 (50.0)
*Categories not mutually exclusive.
†Topic of research identified by the funders for which collaborative
applications are invited as opposed to an open call in which the
applicants suggest the topic of research.
Table 2 Trial participant and design characteristics
Trial participant and design
characteristics (N=90) n (%)
Age group
Adults only 69 (76.7)
Paediatrics only 15 (16.7)
Adults and paediatrics 5 (5.6)
Unclear 1 (1)
Gender
Female 6 (6.7)
Male 0 (0)
Male and female 84 (93.3)
Recruiting newly diagnosed patients 24 (26.7)
Trial recruitment setting*
Secondary 68 (61)
Primary 53 (58.9)
Community 12(13.3)
Emergency 8 (8.9)
Tertiary 6 (6.7)
Social care 6 (6.7)
Blinded trial† 43 (47.8)
Clinician blind 15/43 (34.9)
Participant blind 19/43 (44.2)
Trial involves a placebo 14 (15.6)
If a placebo is involved, do all participants
get an active intervention?
5/14 (35.7)
*Categories not mutually exclusive.
†Twenty-three trials in which blinding only related to the outcome
assessor.
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responsive in 6; a member of the TSC in 8; unclear in 5
and other in 2. Table 4 provides a summary of the speci-
ﬁcation of PPI within the outline applications by the
disease area. The numbers of outline applications by
year with and without details of PPI are displayed in
ﬁgure 1, with ﬁgure 2 showing the percentage of
applications with PPI. Figure 1 shows a general trend for
increasing the number of funded applications; however,
the proportion of those containing PPI ﬂuctuates,
ranging from approximately one half to two-thirds
(ﬁgure 2), with the exception of 2003, for which only
one application was available.
Table 3 Summary of stages of PPI by stage and role
Stage Number of outline
applications
N (%) n=90
Role Number of
outline
applications CommentsOutline (O) Full (F) Trial (T) O F T
Y Y Y 19 (21.3) M M M 13 2 had multiple approaches alongside
M in the main trial (TSC; TSC plus R)
R M M 1
R R R 2
R U U 1
U R R 1
U U U 1
Y Y NS 2 (2.2) R R – 1
O R – 1 O=described as informal contacts
Y NS Y 2 (2.2) R – O 1 O=scale development
R – TSC 1 Consulted in pilot study
Y NS NS 3 (3.4) O – – 3 O=clinical studies group; survey;
Service user Forum
NS Y Y 8 (9.0) – M M 3 In 1 also TSC & R in trial
– R R 2 In 1 TSC too
– R M 1
– U U 2
NS Y NS 1 (1.1) – R – 1
NS NS Y 12 (13.5) – – M 3
– – R 1
– – TSC 7 2 above also listed TSC alongside
higher order approach
– – O 1 Piloted and then refined with users
NS NS NS 40 (44.9) – – – 40
NS U U 2 (2.2) – U U 1
– M M 1 Unclear when PPI initiated but when
it starts it is at M
M, managerial; NS, none specified; O, other; PPI, patient and public involvement; R, responsive; TSC, member of Trial Steering Committee;
U, unclear; Y, yes.
Table 4 PPI specified within the outline application by disease area
Disease/condition category
PPI details in outline text
Totals p ValueYes No
Pregnancy and childbirth 1 (50.0) 1 (50.0) 2 (2.2) 0.51*
Cancer 1 (33.3) 2 (66.7) 3 (3.3)
Stroke 3 (75.0) 1 (25.0) 4 (4.4)
Mental health 8 (61.5) 5 (38.5) 13 (14.4)
Paediatrics† 8 (53.3) 7 (46.7) 15 (16.7)
Degenerative neurological disorders 4 (100.0) 0 (0.0) 4 (4.4)
Other 24 (49.0) 25 (51.0) 49 (54.4)
Total 49 (54.4) 41 (45.6) 90 (100.0)
*Fisher’s exact test.
†Paediatrics cuts across specific topics. For example, a trial may be in a mental health disorder affecting young people. All such trials were
classed as being ‘paediatric’. To avoid double counting two trials in diabetes, three in mental health, and one in neurological were classified
within the paediatric category only.
PPI, patient and public involvement.
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Figure 3 and table 5 provide the data by year for spe-
ciﬁc conditions. Both of the diabetes trials were in chil-
dren and were coded as paediatric, and there were no
HIV/AIDS trials within the cohort. Figure 3 suggests
declining rates of PPI in paediatric and mental health,
with other areas including the general other category
demonstrating an increase over time; however, as shown
in table 5, the numbers in some categories were small.
Table 6 shows the associations between trial design
characteristics and characteristics of the condition under
study, with consideration of PPI within the outline
application.
Of the intervention aims, numbers were too small to
draw conclusions about involvement in diagnostic
studies, but prevention trials more frequently described
PPI than intervention trials. Trials involving educational,
behavioural or physical interventions were more likely to
have provided details of PPI in the outline application
than trials involving drugs or devices. Surgical trials were
signiﬁcantly less likely to have provided details of PPI.
The settings for trial recruitment did not appear to
impact on speciﬁcation of PPI, while recruiting partici-
pants at the point of diagnosis was associated with less PPI.
Forty-three trials were described as being blind and
these trials were associated with increased frequency of
describing PPI. Of these trials 23 involved blinding of
the outcome assessor only. Only 14 trials involved a
placebo, and of these, participants in 5 trials all received
an active intervention with the placebo used as a double
dummy. The allocation of a placebo only to one arm of
the trial was signiﬁcantly associated with greater fre-
quency of PPI detail.
Only two trials were in rare conditions. Both of these
trials provided detail of PPI within the outline applica-
tion. While there appeared to be some increase in
describing PPI when the condition was long term there
did not appear to be any inﬂuence based on impact of
life expectancy.
Board comments on outline applications
NIHR HTA Board minutes were available for 77 (77/110
70%) outline applications. Only nine (9/77 12%) Board
Figure 1 Number of outline applications by the year in which
the application was made (PPI, patient and public
involvement).
Figure 3 Cumulative percentages of outline applications by
disease/condition (PPI, patient and public involvement).
Figure 2 Percentage of outline applications containing
patient and public involvement (PPI) details by the year in
which the application was made. The number of trials
included within each year is indicated at the top of each bar.
Table 5 Number of cumulative applications by disease/
condition category
Cumulative number of applications by
year
2003 2004 2005 2006 2007 2008
Mental health 1 4 4 6 10 13
Cancer 1 1 3 3
Paediatrics 5 8 11 15
Degenerative
neurological
1 2 4
Pregnancy and
childbirth
1 2
Stroke 1 1 4
Other 3 16 36 49
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minutes gave feedback on PPI representation and two of
these did so indirectly (table 7). One comment was sup-
portive of the PPI described in the outline, which
involved a PPI contributor as a co-applicant.
The corresponding outline applications were also
available for 64 (84%) of the 77 applications for which
Board minutes were available. Of these applications 25
(25/64=39%) gave no information about PPI.
Eight of the nine sets of Board comments that were
made about PPI expressed the need for applicants to
increase PPI. Six contained no detail about PPI within
the application. Of these six, two were drug trials, three
were exercise interventions and one was comparing an
invasive with a non-invasive intervention. Two were
recruiting participants with addiction: smoking and
alcohol; two were recruiting elderly participants, one was
recruiting infants, and one was recruiting participants
with a long-term chronic debilitating condition.
In the two outline applications which had given some
details on PPI, comments from the Board were to
further increase PPI. In one application the PPI contri-
butors were employed within an NIHR condition-speciﬁc
Table 6 PPI specified within the outline application by condition and trial characteristics
Intervention
PPI details in the outline
application
Total
N=90 n (%) p Value
Yes No
n (%) n (%)
Aim of intervention
Treatment 40 (54.1) 34 (45.9) 74 (82.2) 0.66*
Prevention 8 (61.5) 5 (38.5) 41 (45.6)
Diagnostic 1 (33.3) 2 (66.7) 3 (3.3)
Nature of intervention†
Drug 16 (51.6) 15 (48.4) 31 (34.4) 0.70
Device 7 (46.7) 8 (53.3) 15 (16.7) 0.51
Surgery 4 (25.0) 12 (75.0) 16 (17.8) 0.01
Education 6 (60.0) 4 (40.0) 10 (11.1) 0.75*
Behavioural 11 (64.7) 6 (35.3) 17 (18.9) 0.35
Physical 8 (72.7) 3 (27.3) 11 (12.2) 0.19
Setting†
Primary care 10 (47.6) 11 (52.4) 21 (23.3) 0.47
Secondary care 30 (56.6) 23 (43.4) 53 (58.9) 0.62
Emergency care 4 (50.0) 4 (50.0) 8 (8.9) 1.00*
Community 6 (50.0) 6 (50.0) 12 (13.3) 0.77
Social care 4 (66.7) 2 (33.3) 6 (6.7) 0.68*
Tertiary 4 (66.7) 2 (33.3) 6 (6.7) 0.68*
Blinding
Yes‡ 30 (69.8) 13 (30.2) 43 (47.8) 0.01
No 19 (40.4) 28 (59.6) 47 (52.2)
Involved a placebo
No placebo 39 (51.3) 37 (48.7) 76(84.4) 0.17
Placebo§ 10 (71.4) 4 (28.6) 14 (15.6)
Received an active intervention
Received Placebo only¶ 8 (88.9) 1 (11.1) 9 (10.0) 0.04*
Received an active intervention 41 (50.6) 40 (49.4) 81 (90.0)
Recruitment at diagnosis
Yes 8 (33.3) 16 (66.7) 24 (26.7) 0.02
No 41 (62.1) 25 (37.9) 66 (73.3)
Long-term condition
Yes 31 (60.8) 20 (39.22) 51 (56.7) 0.17
No 17 (47.2) 19 (52.8) 36 (40)
Impact of condition on life expectancy
None 36 (57.1) 27 (42.9) 63 (70.0) 0.72
General shortening 7 (50.0) 7 (50.0) 14 (15.6)
Rapid mortality 6 (46.2) 7 (53.9) 13 (14.4)
*Fishers exact test.
†Categories are not mutually exclusive.
‡Includes 23 trials in which only the outcome assessor was blind.
§Five trials used a double-dummy technique.
¶Groups receiving placebo did not receive an active intervention.
PPI, patient and public involvement.
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network in roles relating to PPI. These individuals also
had relevant experience as carers or patients of the con-
dition. In the other application the PPI contributor was
a co-applicant with an unrelated clinical background
(midwife) and was the mother of a child with the condi-
tion being studied.
DISCUSSION
Summary
This is the ﬁrst study to systematically investigate whether
and how PPI is described within the earliest stages of trial
development across a cohort of studies. The cohort
covers a variety of clinical conditions and interventions,
and this study is the ﬁrst to examine associations between
trial design, intervention and condition characteristics
and applicants’ plans for PPI. Key ﬁndings are sum-
marised in box 2. PPI was described in only half of the
applications at the outline stage, with only a quarter indi-
cating that PPI contributions were enlisted at the outline
application stage itself. There was some evidence to
suggest that the further the trial deviates from routine
clinical practice the more likely the application is to
describe PPI, and PPI was particularly frequent in appli-
cations for blinded trials or trials allocating participants
to placebo only. This may indicate the beginning of a risk-
based approach to PPI. However, applications for trials
recruiting at the point of diagnosis or trials with surgical
interventions were less likely to describe PPI. For trials
recruiting at the time of diagnosis this may reﬂect the dif-
ﬁculty of identifying PPI representatives close to the time
of their diagnosis, while for surgical trials this may reﬂect
the lower frequency and therefore evolution of research
practices within their RCTs.
There were some indications that planned PPI contri-
butions would increase as the application progressed
from outline to full application through to funded trial.
However, the proportion of applications describing PPI
did not appear to increase across the years of the
cohort.
Strengths and weaknesses of the study
This study used a cohort of trials funded by the NIHR
HTA programme. To be eligible for inclusion within the
cohort, applicants were required to have received
funding for the trial between 2006 and 2010.
Documentation could not be made available for unsuc-
cessful applications. Consequently this study does not
link details of PPI within the application to the success-
ful award of the grant. However, while the HTA
Programme encouraged PPI during this period, via its
guidance notes to applicants and web information, and
allowed it to be budgeted for, PPI was not mandatory
within the period of the cohort, and that on its own
would not have led to a decision that the outline appli-
cation should not progress. As the cohort was identiﬁed
by receipt of funding during the period rather than on
Table 7 Board comments on outline applications relating to patient and public involvement (PPI)
Unique
identifier
Year outline
application
submitted Text from Board minutes for outline applications
28 2007 The applicants should consider involvement of disadvantaged groups.
65 2006 There was no clear service user involvement and this needs to be addressed.
70 2006 The Board would be pleased to see letters of support from appropriate PCTS and patient
groups that the trial is feasible. The Board wish to see patient and public involvement in any
full proposal.
34 2008 The Board noted it was a well designed study that has received input from patients.
92 2007 Ethical aspects including acceptability to parents must be fully considered.
39 2008 Consideration should be given to increasing service user involvement.
42 2008 Patient representation is required.
98 2007 An explanation and demonstration of acceptability to parents must be included.
105 2007 The application would benefit from strong patient and public involvement.
Box 2
What is already known on this topic
▸ There is an increased awareness of the need for patient/public
involvement in research
▸ There is an expectation from funders of research that patient
and public involvement (PPI) should be incorporated within
that research
▸ There is selective reporting of PPI within the published
literature.
What this study adds
▸ A systematic analysis of PPI in a cohort of randomised con-
trolled trials receiving funding from the National Institute of
Health Research Health Technology Assessment programme
between 2006 and 2010
▸ Only half of applications consider PPI within the early stages
of the development of the research, with only a quarter having
involvement within the development of the outline application
itself
▸ There is evidence that particular conditions, and design con-
siderations, impact on whether PPI is likely to be considered
within the early stages of development
▸ There is insufficient consideration of PPI at the early stages by
funding Boards.
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the year that the outline application was submitted for
consideration, fewer trials were available in the extremes
of the cohort, but this approach was a consequence of
the archiving system. The key limitation is the historical
nature of this cohort. The period of the cohort should
be considered when generalising the ﬁndings to the
present day, due to revisions to the guidance for appli-
cants and application forms in relation to PPI. From
2012 HTA boards have started to include PPI member-
ship, and the standard NIHR application form has been
introduced, with revised sections requiring applicants to
clearly deﬁne their PPI involvement with guidance notes
to applicants clearly stating that there is now an ‘expect-
ation’ for ‘active involvement’ of patients and the public
in the research it supports (http://www.nets.nihr.ac.
uk/__data/assets/pdf_ﬁle/0005/67685/OutlineGuidance
NotesSAF.pdf, last accessed 28 April 2014). In addition,
attitudes towards PPI may have changed and this may
inﬂuence how early researchers engage with PPI contri-
butors. However, further research is needed to consider
this and its potential for impact.
It has been argued that researchers use a tokenistic
approach to patient involvement and the level of detail
on PPI plans within this cohort may lend some strength
to that argument. In order to summarise the details of
PPI across the cohort some means of categorising
descriptions of PPI activity was necessary. The lack of
detail provided within the applications required clear
coding rules to be established; however, these were
clearly documented. Establishing coding rules was con-
sidered reasonable, as within the peer review of an
outline application similar assumptions would need to
be made by reviewers considering the PPI descriptions
provided.
The results should be interpreted with some caution,
owing to the small numbers within some categories, and
this caution applies to the results of the statistical tests,
which were not powered to detect differences and
should be considered as exploratory.
Strengths and weaknesses in relation to other studies
There are many examples or accounts of PPI within the
published literature focusing on particular trials or topic
areas9–12 and concerns have been raised about selective
reporting.1 This is the ﬁrst study to systematically investi-
gate PPI early in the development of funding applica-
tions and across a wide range of trials. A previous paper
on PPI within clinical trial units13 (CTUs) concluded
that involvement appears to be growing. While the
majority of applications within the current cohort
included collaborations with CTUs, we found no clear
trend of PPI activity increasing within this time. A stand-
ard operating procedure (SOP) for PPI in CTUs has
been recently developed; however, its focus is on PPI
after funding has been awarded.14 The SOP suggests
that 1% of the research budget be allocated to PPI;
however, other more detailed costing models are
available.15
If PPI is accepted as the best practice with early
involvement, as it provides the greatest opportunity to
maximise its contribution, then implementation of PPI
and its descriptions within outline applications need to
be increased and improved with justiﬁcations and
methods for the approaches taken. It is noteworthy that
no application within the cohort examined provided this
level of information. The NIHR HTA programme has
made changes to the outline application form, which
now requests details of PPI and justiﬁcation if it is
absent. This may lead to increased descriptions but may
not be associated with better involvement: a view which
has some support from the current guidance, which
states, “Whilst patient and public involvement (PPI) may
not always be needed for all types of research, it is always
relevant for HTA trials. Many PPI sections on the appli-
cation are unconvincing to our consumer referees and
Board members.” (http://www.nets.nihr.ac.uk/funding/
hta-researcher-led/Preparing-a-full-application-for-the-
Clinical-Trials-and-Evaluation-Board.pdf, last accessed
20 November 2013).
Descriptions should specify how PPI has been incorpo-
rated within the development of the outline application
and the plans for involvement should the application pro-
gress. However, the research community needs to con-
sider the challenges facing researchers in developing PPI
at the early design stage. In particular, the often short
timeframes within which outline applications have to be
developed and PPI contributors identiﬁed, and the lack
of funding to support this work prior to the grant award,
are major obstacles to enhancing PPI at an early stage in
trial development. In England, a PPI bursary scheme has
recently been launched by some of the NIHR Research
Design Service (RDS), but is limited to those in receipt of
advice from the RDS and has been shown to be beneﬁ-
cial.16 17 There are few other alternatives to funding
development activity at the pre-award stage.15
Although funding body policies support PPI, this
support was not usually evident in the HTA Board feed-
back to applicants at the outline stage. This may be due
to the difﬁculties in assessing PPI given the lack of detail
provided within applications, or indicate that at the
outline stage the weight of the decision about progres-
sion is on the perceived relevance of the question and
design. When feedback about PPI was given this did not
provide any guidance on how it should be addressed.
Statements about the need to improve PPI should be
supported with guidance on what PPI contributions
would be appropriate within the trial being considered.
Peer reviewers and Board members who are asked to
comment on PPI should be supported in doing so.
Adoption of critical appraisal guidelines may be beneﬁ-
cial in achieving this.18 From 2012 NIHR HTA funding
Boards include a PPI representative. The impact of this
on the frequency of comments and their content is not
yet known.
Our ﬁndings also raise questions about what sort of
experience qualiﬁes (or disqualiﬁes) individuals to be
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PPI contributors, as identiﬁed within the comments
from the Board. Regardless of whether they have rele-
vant personal experience, should individuals with profes-
sional clinical or research experience become PPI
contributors? Does an individual’s experience in a pro-
fessional capacity somehow weaken their ability to adopt
a patient or carer perspective, or does a professional
background strengthen a person’s ability to contribute
to the research? Current NIHR HTA guidance states that
“To achieve the aim of bringing fresh eyes to the work of
the HTA programme a patient or member of the public
should not normally be a health practitioner, manager
or researcher” (http://www.hta.ac.uk/PPIguidance/
section1_2.shtml, last accessed 26 September 2013).
There is also confusion about whether it is acceptable
for individuals who have a PPI role in a professional cap-
acity as well as relevant personal experience to provide
PPI. Concerns have been previously raised about PPI
representatives becoming professionalised,19 and evi-
dence is needed on whether this is a legitimate concern.
This should be rationalised against the fact that PPI
representatives are generally individuals who are selected
by researchers based on their attributes, and their ability
to ‘represent’ the wider population of interest may be
questioned, however, this may not impact their ability to
communicate their unique ‘lay’ perspective.20
Future research
The lack of detail on PPI at the early stages of research
development needs to be addressed. There is a keen
interest in determining whether the perceived beneﬁts
of PPI lead to tangible beneﬁts for research. The activ-
ities of PPI contributors need to be tracked to provide
insights on when and what type of involvement may be
linked to impact. Further research tracing the evolution
of PPI within this cohort is being undertaken.
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